KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Research & Development (2018 - 2025)

Historic Research & Development for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q3 2025 value amounting to $8.4 million.

  • Aurinia Pharmaceuticals' Research & Development rose 17682.97% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year increase of 2973.46%. This contributed to the annual value of $20.8 million for FY2024, which is 5812.94% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Research & Development stood at $8.4 million for Q3 2025, which was up 17682.97% from $7.4 million recorded in Q2 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Research & Development peaked at $20.1 million during Q3 2021, and registered a low of $3.0 million during Q3 2024.
  • Moreover, its 5-year median value for Research & Development was $9.9 million (2022), whereas its average is $9.4 million.
  • Its Research & Development has fluctuated over the past 5 years, first surged by 22895.0% in 2023, then crashed by 7760.38% in 2024.
  • Aurinia Pharmaceuticals' Research & Development (Quarter) stood at $11.1 million in 2021, then decreased by 11.47% to $9.9 million in 2022, then increased by 3.63% to $10.2 million in 2023, then decreased by 20.74% to $8.1 million in 2024, then rose by 4.05% to $8.4 million in 2025.
  • Its Research & Development was $8.4 million in Q3 2025, compared to $7.4 million in Q2 2025 and $5.7 million in Q1 2025.